Journal of Rheumatic Diseases

Cited by CrossRef (6)

  1. Ji-Won Kim. Are nonsteroidal anti-inflammatory drugs safe for the kidney in ankylosing spondylitis?. J Rheum Dis 2023;30:139
    https://doi.org/10.4078/jrd.2023.0033
  2. Subin Hwang, Ye‐Jee Kim, Soo Min Ahn, Bon San Koo. Incidence rate of chronic kidney disease and its association with long‐term nonsteroidal anti‐inflammatory drug use in ankylosing spondylitis: A nationwide population‐based study. Int J of Rheum Dis 2024;27
    https://doi.org/10.1111/1756-185X.15310
  3. S. Sülükcü, S. Uslu. Assessment of liver and kidney function in patients with ankylosing spondylitis on long-term non-steroidal anti-inflammatory drug therapy. Reumatismo 2024
    https://doi.org/10.4081/reumatismo.2024.1732
  4. O. I. Butranova, S. K. Zyryanov. Selection of NSAIDs for rational pharmacotherapy of chronic musculoskeletal pain: a clinical pharmacologist's perspective. RJTAO 2024;16:87
    https://doi.org/10.14412/2074-2711-2024-2-87-94
  5. Min Wook So, Aran Kim, Seung-Geun Lee. DA-9601 has protective effects comparable to those of proton pump inhibitor and rebamipide against nonsteroidal anti-inflammatory drugs-induced upper and lower gastrointestinal bleeding in patients with rheumatoid arthritis: A nationwide study using Korean Health Insurance Review and Assessment Service database. 2024;103:e38801
    https://doi.org/10.1097/MD.0000000000038801
  6. Hong Ki Min, Hae-Rim Kim, Sang-Heon Lee, Bora Nam, Ji Hui Shin, Tae-Hwan Kim. Risk of disease flare in spondyloarthritis patients after tapering tumor necrosis factor inhibitors: A meta-analysis and literature review. International Immunopharmacology 2024;134:112167
    https://doi.org/10.1016/j.intimp.2024.112167